Compare Stocks: AUTL, VCEL, BHVN, and NBTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.94 +1.0%	$1.95	$1.18 ▼ $2.58	$511.03M	2.1	1.54 million shs	1.77 million shs
BHVN Biohaven	$13.58 -2.3%	$14.41	$7.48 ▼ $18.57	$2.10B	1.28	3.67 million shs	6.43 million shs
NBTX Nanobiotix	$33.05 -7.9%	$39.22	$10.58 ▼ $57.14	$1.82B	0.81	145,096 shs	149,344 shs
VCEL Vericel	$40.02 0.0%	$43.31	$28.95 ▼ $49.32	$2.05B	1.04	474,620 shs	1.13 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+1.04%	+3.19%	-23.62%	+28.48%	+52.76%
BHVN Biohaven	-1.86%	+6.43%	-4.18%	+0.10%	-7.65%
NBTX Nanobiotix	-7.89%	-10.70%	-27.19%	-8.88%	+211.65%
VCEL Vericel	-0.02%	+4.38%	-8.15%	-0.20%	+33.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.94 +1.0%	$1.95	$1.18 ▼ $2.58	$511.03M	2.1	1.54 million shs	1.77 million shs
BHVN Biohaven	$13.58 -2.3%	$14.41	$7.48 ▼ $18.57	$2.10B	1.28	3.67 million shs	6.43 million shs
NBTX Nanobiotix	$33.05 -7.9%	$39.22	$10.58 ▼ $57.14	$1.82B	0.81	145,096 shs	149,344 shs
VCEL Vericel	$40.02 0.0%	$43.31	$28.95 ▼ $49.32	$2.05B	1.04	474,620 shs	1.13 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+1.04%	+3.19%	-23.62%	+28.48%	+52.76%
BHVN Biohaven	-1.86%	+6.43%	-4.18%	+0.10%	-7.65%
NBTX Nanobiotix	-7.89%	-10.70%	-27.19%	-8.88%	+211.65%
VCEL Vericel	-0.02%	+4.38%	-8.15%	-0.20%	+33.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.88	Moderate Buy	$10.00	415.46% Upside
BHVN Biohaven	2.59	Moderate Buy	$18.69	37.65% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$46.67	41.20% Upside
VCEL Vericel	2.67	Moderate Buy	$58.40	45.93% Upside

Current Analyst Ratings Breakdown

Latest AUTL, VCEL, BHVN, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	BHVN Biohaven	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/15/2026	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$64.00
9/10/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
9/8/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$23.00 ➝ $19.00
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
8/27/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/26/2026	BHVN Biohaven	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$30.00
8/13/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$18.00 ➝ $19.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$75.39M	6.85	N/A	N/A	$0.67 per share	2.90
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
NBTX Nanobiotix	$36.87M	45.38	N/A	N/A	($1.97) per share	-16.78
VCEL Vericel	$276.26M	7.42	$0.56 per share	72.06	$7.01 per share	5.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
NBTX Nanobiotix	-$27.11M	N/A	N/A	330.50	N/A	N/A	N/A	N/A	9/29/2026 (Estimated)
VCEL Vericel	$16.52M	$0.47	85.15	47.64	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)

Latest AUTL, VCEL, BHVN, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2026	H1 2026	NBTX Nanobiotix	-$0.4846	N/A	N/A	N/A	$1.73 million	N/A
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	1.04	4.89	4.40
BHVN Biohaven	21.23	4.73	4.73
NBTX Nanobiotix	N/A	1.09	1.09
VCEL Vericel	N/A	5.04	4.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
BHVN Biohaven	88.78%
NBTX Nanobiotix	38.81%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
BHVN Biohaven	13.80%
NBTX Nanobiotix	3.45%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	752	266.16 million	197.76 million	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
NBTX Nanobiotix	97	50.62 million	48.87 million	Not Optionable
VCEL Vericel	398	51.21 million	47.32 million	Optionable

AUTL, VCEL, BHVN, and NBTX Headlines

Recent News About These Companies

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

September 14, 2026 | seekingalpha.com

Vericel Corporation $VCEL Shares Sold by Wellington Management Group LLP

September 12, 2026 | marketbeat.com

Scholtz & Company LLC Buys New Stake in Vericel Corporation $VCEL

September 10, 2026 | marketbeat.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

September 8, 2026 | globenewswire.com

The Manufacturers Life Insurance Company Makes New Investment in Vericel Corporation $VCEL

September 5, 2026 | marketbeat.com

115,630 Shares in Vericel Corporation $VCEL Bought by Legal & General Group Plc

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Vericel Corporation $VCEL

September 2, 2026 | marketbeat.com

Jupiter Topco LLC Makes New $4.42 Million Investment in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Man Group plc Buys New Shares in Vericel Corporation $VCEL

September 1, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 31, 2026 | marketbeat.com

Formula Growth Ltd. Makes New $1.15 Million Investment in Vericel Corporation $VCEL

August 28, 2026 | marketbeat.com

Deutsche Bank AG Purchases Shares of 64,404 Vericel Corporation $VCEL

August 27, 2026 | marketbeat.com

EFG International AG Purchases Shares of 127,642 Vericel Corporation $VCEL

August 26, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 8,092,226 Vericel Corporation $VCEL

August 26, 2026 | marketbeat.com

398,365 Shares in Vericel Corporation $VCEL Bought by Osterweis Capital Management Inc.

August 25, 2026 | marketbeat.com

William Blair Investment Management LLC Purchases New Shares in Vericel Corporation $VCEL

August 22, 2026 | marketbeat.com

Madison Asset Management LLC Acquires Shares of 50,116 Vericel Corporation $VCEL

August 21, 2026 | marketbeat.com

Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Lisanti Capital Growth LLC Acquires New Holdings in Vericel Corporation $VCEL

August 20, 2026 | marketbeat.com

Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 4,500 Shares

August 1, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, VCEL, BHVN, and NBTX Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.94 +0.02 (+1.04%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.94 +0.01 (+0.26%)

As of 09/18/2026 07:50 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Biohaven NYSE:BHVN

$13.58 -0.31 (-2.26%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$13.40 -0.17 (-1.26%)

As of 09/18/2026 07:30 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Nanobiotix NASDAQ:NBTX

$33.05 -2.83 (-7.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$33.20 +0.15 (+0.45%)

As of 09/18/2026 07:30 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Vericel NASDAQ:VCEL

$40.02 -0.01 (-0.02%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$40.02 +0.00 (+0.01%)

As of 09/18/2026 07:30 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, VCEL, BHVN, and NBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, VCEL, BHVN, and NBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, VCEL, BHVN, and NBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, VCEL, BHVN, and NBTX Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Biohaven NYSE:BHVN

Nanobiotix NASDAQ:NBTX

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, VCEL, BHVN, and NBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, VCEL, BHVN, and NBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, VCEL, BHVN, and NBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, VCEL, BHVN, and NBTX Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Biohaven NYSE:BHVN

Nanobiotix NASDAQ:NBTX

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools